40 mg胶囊剂型。Engineered using cutting-edge PCR technology, the AmoyDx® PLC Panel enables the simultaneous detection of activation alterations across 11 critical driver genes ( EGFR , ALK , ROS1 , KRAS , BRAF , HER2 , RET , MET , NTRK1 , NTRK2 , NTRK3 ) and identifies actionable mutations in seven of these genes ( EGFR , ALK , ROS1 , BRAF , MET ex14 skipping, KRAS,RET)直接与16种目标NSCLC疗法相关。该批准表示在精确癌症治疗中向前迈出的变革一步,将快速,敏感的检测与显着增强的潜力相结合